CA
CPRX

Cetera Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Cetera Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$401K Buy
+25,172
New +$379K ﹤0.01% 1749

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cetera Advisors's CPRX Position: Q1 2024 in Review

Cetera Advisors opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2024: 25,172 shares worth $401K. The stake represents ﹤0.01% of the portfolio and ranks #1749 among its holdings.

269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

  • Cetera Advisors held 25,172 shares of Catalyst Pharmaceutical worth $401K as of Q1 2024.
  • Catalyst Pharmaceutical was a new Cetera Advisors position in Q1 2024.
  • Catalyst Pharmaceutical made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1749 holding.
  • 269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.